Bulletin
Investor Alert

Topics

Health and Human Services Department

6:51 p.m. March 10, 2021 - MarketWatch
COVID-19 antibody drug effective, say Glaxo, VirA monoclonal-antibody drug reduced hospitalizations or death from Covid-19 by 85% compared with a placebo in a clinical trial, said Vir Biotechnology Inc. and GlaxoSmithKline PLC, the drug's developers.
10:01 a.m. Dec. 28, 2020 - By Ciara Linnane
U.S. has had more than 19 million COVID-19 cases, and Fauci is getting worried about a post-holiday surge Relief as Trump signs relief bill and Novavax is starting a Phase 3 trial of its vaccine candidate in the U.S. and MexicoThe global tally for confirmed cases of the coronavirus-borne illness COVID-19 topped 81 million on Monday, while the U.S. case tally topped 19 million, and experts warned the next few weeks will be hard after many Americans traveled over the Christmas holiday.
5:31 a.m. Dec. 28, 2020 - By Ciara Linnane
Novavax starts Phase 3 COVID vaccine trial with plans to enroll 30,000 volunteers in U.S. and MexicoNovavax Inc. said Monday it is starting a late-stage trial of its COVID-19 vaccine candidate with plans to enroll up to 30,000 volunteers at about 115 sites in the U.S. and Mexico. The trial is being supported by partners of Operation Warp Speed, the federal government program that aims to quickly develop vaccines and therapies, including the Department of Defense and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response. Barda is providing up to $1.6 billion to fund the trial under a Department of Defense agreement. The trial will be randomized, placebo-controlled and will evaluate the efficacy of the treatment, called NVX-CoV2373, in patients aged 18 and older. Shares were slightly higher Monday, and have gained more than 3,000% in 2020 on hopes for the vaccine.
10:22 a.m. Dec. 10, 2020 - By Ciara Linnane
U.S. sets record one-day death toll from coronavirus as FDA committee meets to review Pfizer–BioNTech vaccine FDA head says initial assessment is ‘this is a vaccine that does meet our criteria. ... But we do want to hear from the vaccine advisory committee.’The U.S. set fresh records for single-day fatalities from the coronavirus illness COVID-19 and hospitalizations, as a U.S. regulatory advisory committee gathered to offer its verdict on the vaccine developed by Pfizer Inc. and its German partner BioNTech SE.
3:18 a.m. Dec. 10, 2020 - By Ciara Linnane
Moderna doses first patients in Phase 2/3 study of COVID-19 vaccine in adolescents Moderna Inc. said Thursday it has dosed the first participants in a Phase 2/3 study of its COVID-19 vaccine candidate in adolescents aged 12 to less than 18. The study is being conducted in collaboration with Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. The biotech is aiming to generate data in the spring of 2021 that will support the use of the vaccine in that age group, Chief Executive Stéphane Bancel said in a statement. The trial will be randomized and include a control group and the company is aiming to enroll 3,000 participants in the U.S. who will be monitored for 12 months after the second dose. Shares rose 1.5% in premarket trade, but have gained 701% in the year to date, while the SPDR S&P Biotech ETF has gained 44% and the S&P 500 has gained 13.7%.
10:26 a.m. Dec. 9, 2020 - By Ciara Linnane
U.S. coronavirus case tally climbs to 15 million from 14 million in just five days U.S. sets fresh record for COVID-19 hospitalizations; Angela Merkel pleads with Germans to limit gatherings during holidaysThe global case tally for the coronavirus illness COVID-19 climbed above 68 million on Wednesday and the U.S. tally rose above 15 million as the virus continued to race across the nation, filling hospitals with record numbers of patients
4:36 a.m. Dec. 4, 2020 - By Ciara Linnane
Moderna to provide Israel health ministry with additional 4 million doses of its COVID-19 vaccine candidateModerna Inc. said Friday it is amending its supply agreement with the Israeli health ministry and will provide an additional 4 million doses of its experimental COVID-19 vaccine mRNA-1273. The amendment brings the total number of doses secured by Israel to 6 million. The vaccine is currently awaiting review for an emergency use authorization in the U.S., and has been submitted for approval in Europe. The company has initiated the rolling regulatory review process with the Ministry of Health in Israel, it said in a statement. The vaccine has proven to have 94% efficacy in a preliminary analysis of a Phase 3 trial conducted on 196 cases. The trial involves more than 30,000 participants and is being conducted with the NIAID part of the NIH and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. Moderna is also working to scale up manufacturing and aims to deliver about 500 million doses a year and up to 1 billion doses a year starting in 2021. Shares were slightly lower premarket, but have gained 704% in the year to date, while the JSPDR S&P 500 Biotech ETF has gained 41% and the S&P 500 [ has gained 13%.
10:55 a.m. Nov. 25, 2020 - By Ciara Linnane
Hospital workers called exhausted as U.S. records highest number of COVID deaths since May Parts of Europe are reporting declining cases and Sicily has asked Cuba to send doctors and nursesThe U.S. recorded the highest number of deaths from the coronavirus illness COVID-19 since May on Tuesday, and continues to average close to 200,000 new cases a day, with hospitals across the nation reporting exhausted health care workers and steadily filling intensive care units.
4:31 a.m. Nov. 24, 2020 - By Davide Mamone
It’s 2:30 a.m. in Wyoming: ‘You’re holding a smartphone to let a husband say goodbye to his wife via FaceTime after 60 years of marriage’ Doctors and nurses in North Dakota and Wyoming tell MarketWatch what it's like on the front lines of COVID-19Doctors and nurses in North Dakota and Wyoming tell MarketWatch what it's like on the front lines of COVID-19.
2:41 a.m. Nov. 17, 2020 - By Ciara Linnane
Moderna’s COVID-19 vaccine candidate sparks market rally after achieving 94.5% efficacy in late-stage trial and requires only standard refrigeration Biotech says vaccine remains stable at refrigerated temperatures for longer times, so distribution could be a lesser challengeModerna Inc. said Monday its COVID-19 vaccine candidate met its primary endpoint in a Phase 3 trial, demonstrating 94.5% efficacy, a far higher benchmark than originally expected, sparking a broad-based market rally.
3:51 a.m. Nov. 16, 2020 - By Ciara Linnane
UPDATE: Moderna shares soar premarket after COVID-19 vaccine candidate achieves 94.5% efficacy in Phase 3 trialModerna Inc. shares soared 16% in premarket trade Monday, after the biotech said its COVID-19 vaccine candidate met its primary endpoint in a Phase 3 trial, demonstrating 94.5% efficacy. The news was shared in a news release and has not yet been published as a preprint or in a peer-reviewed medical journal. The company said it plans to submit an Emergency Use Authorization with the U.S. Food and Drug Administration in the coming weeks and expects it to be based on the final analysis of 151 cases and a median follow-up for more than two months. The Phase 3 trial enrolled more than 30,000 participants in the U.S. and is being conducted with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. Moderna said the primary endpoint of the Phase 3 trial is based on the analysis of COVID-19 cases starting two weeks after the second dose of vaccine. The first analysis was based on 95 cases with 90 cases in the placebo group and 5 in the mRNA-1273 group. The 95 cases were in older adults, aged 65 years old and up, and 20 participants identifying as coming from diverse communities, with 12 Hispanic or LatinX, 4 Black or African-American, and 3 Asian Americans and 1 multi-racial person. The trial did not report any significant safety concerns. Last week, Pfizer INnc. and partner BioNTech SE said their vaccine candidate had achieved 90% efficacy in a Phase 3 trial, a far higher benchmark than originally expected. Shares have gained 357% in the year to date, while the S&P 500 has gained 11%.
10:44 p.m. Oct. 11, 2020 - MarketWatch
AstraZeneca advances COVID-19 antibody comboAstraZeneca PLC said Monday that it has received $486 million from the U.S. government to support the development and supply of its long-acting antibody combination AZD7442 for the prevention of Covid-19.
8:12 a.m. Aug. 31, 2020 - By Barbara Kollmeyer
European stocks fall on the last day of August trading Suez surges on deal news, Philips drops on warning European stocks struggled on Monday, in a month that’s set to deliver a 3.3% gain for the region’s main index.
2:39 a.m. Aug. 13, 2020 - By Ciara Linnane
Moderna stock rally fades as analysts weigh in on what U.S. government supply deal means for COVID-19 vaccine pricing ‘We now await visibility on what agreements with other countries might look like but see the news as a positive signal re: Moderna’s potential entry into a commercial space often dominated by big-cap,’ says one analystThe rally in Moderna Inc. shares sparked by news late Tuesday that the U.S. government has ordered 100 million doses of its COVID-19 vaccine candidate dissipated on Wednesday, as analysts weighed in on what the order means for pricing.
12:58 a.m. Aug. 10, 2020 - By Sherri Snelling
Could flu vaccines lower your risk of Alzheimer’s? Research sheds new light Two studies released at the Alzheimer’s Association conference indicate a possible connection between flu and pneumonia shots with reducing or delaying cognitive declineThe studies show ‘vaccines are strongly associated with lower prevalence of dementia,’ says one scientist.
7:16 a.m. July 18, 2020 - By Jaimy Lee
Rule change for how hospitals report coronavirus data to government comes under fire ‘This decision raises more questions than answers,’ said one policy expertA federal dashboard that provides information to the public about COVID-19 data that is provided by hospitals has not been updated since a rapidly implemented rule for how hospitals report that kind of data was put into place.
5:25 a.m. July 4, 2020 - By Jaimy Lee
After months of speculation, investors get excited about Pfizer, BioNTech’s coronavirus vaccine candidate FDA’s new guidelines for vaccine development ‘do not suggest that a widely usable vaccine will be available at ‘warp speed’ in 2020,’ says one analystThe path to a COVID-19 vaccine has started to come into view this week, following the stock-moving disclosures of preliminary clinical data for two candidates and a rigorous new regulatory road map from the Food and Drug Administration.
2:38 p.m. July 1, 2020 - Associated Press
Global health experts criticize U.S. deal to hog supply of coronavirus drug U.S. makes deal with Gilead for 90% of remdesivir for next 3 monthsPublic health experts on Wednesday criticized the U.S. for securing a large supply of the only drug licensed so far to treat COVID-19.
12:08 p.m. May 10, 2020 - By Quentin Fottrell
New estimates on coronavirus fatalities make for chilling reading as U.S. states ease restrictions on social distancing ‘I don’t want to be Mr. Doom and Gloom,’ President Trump said‘I don’t want to be Mr. Doom and Gloom,’ President Trump said.
7:42 a.m. May 9, 2020 - By Jaimy Lee
Infectious-disease doctors ask government to explain how it decides who gets Gilead’s remdesivir Emergency-use authorization for remdesivir states that distribution of the drug will be controlled by the U.S. government, and several organizations have raised questions about access to the drugWithin a week of the Food and Drug Administration authorization of remdesivir as a COVID-19 treatment, clinicians are pushing the Trump administration to clarify how it is selecting which hospitals get access to the drug.
3:19 a.m. May 6, 2020 - By Quentin Fottrell
‘Will some people be affected badly? Yes.’ As Trump says U.S. must reopen soon, question hangs in the air: Can the economy be saved without sacrificing lives? ‘What government does today will literally determine how many people live and how many people die,’ New York Gov. Andrew Cuomo said ‘What government does today will literally determine how many people live and how many people die,’ New York Gov. Andrew Cuomo said.
5:43 a.m. April 29, 2020 - By Mariana Mazzucato
How to make sure the drug companies don’t make off like bandits as we develop a COVID-19 vaccine Ensuring that no one is left behind requires not just unprecedented collective investment, but also a very different approach to innovationStrong health systems, adequate testing capacity, and an effective, universally available vaccine will be key to protecting societies from the coronavirus. But ensuring that no one is left behind requires not just unprecedented collective investment, but also a very different approach
Browse topics:

Filter results by

Location

Us (153)

Asia Pacific (28)

China (28)

Europe (25)

Eu (21)

Latin America (5)

Link to MarketWatch's Slice.